<DOC>
	<DOCNO>NCT02519452</DOCNO>
	<brief_summary>The purpose study evaluate pharmacokinetics safety mixture daratumumab rHuPH20 prepare immediately administration via Subcutaneous ( SC ) delivery ( Part 1 ) CF ( co-formulated daratumumab rHuPH20 preparation ) administration via SC delivery daratumumab ( Part 2 ) .</brief_summary>
	<brief_title>A Study Daratumumab With Addition Recombinant Human Hyaluronidase ( rHuPH20 ) Treatment Participants With Relapsed Refractory Multiple Myeloma</brief_title>
	<detailed_description>This open-label ( identity assign study drug know ) , multicenter , 2-part , Phase 1b dose escalation/expansion study evaluate safety , pharmacokinetics ( study body drug ) , antitumor activity SC delivery daratumumab participant relapse refractory multiple myeloma . Up approximately 53 participant part 1 80 participant part 2 enrol . The purpose Part 1 select appropriate SC therapeutic dose mixture daratumumab rHuPH20 base safety pharmacokinetics . This dose , select part 1 initial dose co-formulated daratumumab rHuPH20 preparation evaluate Part 2 . The purpose Part 2 evaluate SC delivery CF confirm dose level select Part 1 base pharmacokinetics , safety , antitumor activity . Participant 's safety monitor throughout study .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Daratumumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Participants proven multiple myeloma ( MM ) diagnosis accord International Myeloma Working Group ( IMWG ) diagnostic criterion Measurable disease define follow : ( ) immunoglobulin ( Ig ) G myeloma ( serum monoclonal paraprotein [ Mprotein ] level &gt; =1.0 gram/deciliter [ g/dL ] urine Mprotein level great equal ( &gt; = ) 200 milligram [ mg ] /24 hour [ hr ] ; ( b ) IgA , IgD , IgE multiple myeloma ( serum Mprotein level &gt; = 0.5 g/dL urine Mprotein level &gt; = 200 mg/24 hr ) ; ( c ) light chain multiple myeloma ( serum immunoglobulin free light chain &gt; =10 mg/dL abnormal serum immunoglobulin kappa lambda free light chain ratio ) Participant must Eastern Cooperative Oncology Group ( ECOG ) performance status score 0 , 1 , 2 Pretreatment clinical laboratory value must meet protocoldefined parameter Screening phase Man , sexually active woman childbearing potential vasectomy , must agree use adequate contraception method deem appropriate Investigator , must also agree donate sperm study 3 month last dose daratumumab Relapsed refractory disease . Relapse define progression disease initial response previous treatment , 60 day cessation treatment . Refractory disease define less ( &lt; ) 25 percent ( % ) reduction Mprotein progression disease treatment within 60 day cessation treatment Prior treatment less equal ( &gt; = ) 2 treatment line antimyeloma therapy . Prior line therapy must include proteasome inhibitor ( PI ) ( eg , bortezomib , carfilzomib ) immunomodulatory drug ( IMiD ) ( example , thalidomide , lenalidomide , pomalidomide ) order course treatment . Each prior line therapy may consist one agent may include induction , hematopoietic stem cell transplantation , and/or maintenance therapy . Radiotherapy , bisphosphonates , single short course steroid consider prior line therapy Participant receive daratumumab anticluster differentiation 38 ( antiCD38 ) therapies previously Participant receive antimyeloma treatment within 2 week Cycle 1 Day 1 Participant previously receive allogenic stem cell transplant ; participant receive autologous stem cell transplantation ( ASCT ) within 12 week Cycle 1 Day 1 Participant history malignancy ( multiple myeloma ) within 5 year Cycle 1 Day 1 ( exception squamous basal cell carcinoma skin carcinoma situ cervix , malignancy opinion investigator , concurrence sponsor 's medical monitor , consider cure minimal risk recurrence ) Participant exhibit clinical sign meningeal involvement multiple myeloma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Daratumumab ( JNJ-54767414 )</keyword>
	<keyword>Recombinant Human Hyaluronidase</keyword>
</DOC>